Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | CX-2051 |
| Synonyms | |
| Therapy Description |
CX-2051 is an antibody-drug conjugate (ADC) comprising a monoclonal antibody that targets EpCAM linked to a camptothecin derivative, which potentially induces apoptosis in in EpCAM-expressing tumor cells (NCI Drug Dictionary). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| CX-2051 | CX2051|CX 2051 | CX-2051 is an antibody-drug conjugate (ADC) comprising a monoclonal antibody that targets EpCAM linked to a camptothecin derivative, which potentially induces apoptosis in in EpCAM-expressing tumor cells (NCI Drug Dictionary). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06265688 | Phase I | CX-2051 | First In Human Study of CX-2051 in Advanced Solid Tumors | Recruiting | USA | 0 |